From 999be4e309cb0100171e2d2d8f3341d79e8c522c Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 16 Mar 2026 11:49:10 +0000 Subject: [PATCH] extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction Pentagon-Agent: Ganymede --- ...t cost impact inflationary through 2035.md | 6 ++++ ...-cardiovascular-and-metabolic-endpoints.md | 6 ++++ ...ients-undermining-chronic-use-economics.md | 6 ++++ ...eating-largest-per-patient-cost-savings.md | 6 ++++ ...rofits from health rather than sickness.md | 6 ++++ ...mployer-cost-savings-cancer-reduction.json | 32 +++++++++++++++++++ ...-employer-cost-savings-cancer-reduction.md | 17 +++++++++- 7 files changed, 78 insertions(+), 1 deletion(-) create mode 100644 inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 329db7879..b96400859 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -35,6 +35,12 @@ The Cell Press review characterizes GLP-1s as marking a 'system-level redefiniti MA plans' near-universal prior authorization creates administrative friction that may worsen the already-poor adherence rates for GLP-1s. PA requirements ensure only T2D-diagnosed patients can access, effectively blocking obesity-only coverage despite FDA approval. This access restriction compounds the chronic-use economics challenge by adding administrative barriers on top of existing adherence problems. + +### Additional Evidence (challenge) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16* + +Aon's 192K patient study shows medical costs rise 23% in year 1 but only 2% after 12 months (vs 6% for non-users), with diabetes patients showing 6-9 percentage point lower cost growth at 30 months. This suggests GLP-1s are cost-saving for long-term risk-bearers, not inflationary—the 'inflationary through 2035' claim may only apply to short-term payers like employers with high turnover. + --- Relevant Notes: diff --git a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md index 1222d36b5..50358035b 100644 --- a/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md +++ b/domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md @@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr - Nature Medicine: additive benefits with SGLT2 inhibitors - First GLP-1 to receive FDA indication for CKD in T2D patients + +### Additional Evidence (extend) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16* + +Aon study adds cancer risk reduction to the multi-organ protection profile: 50% lower ovarian cancer and 14% lower breast cancer in female users, plus lower rates of osteoporosis, rheumatoid arthritis, and alcohol/drug abuse hospitalizations. The sex-differential in MACE (47% female vs 26% male) suggests organ-specific protection may be stronger in women. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 1f412e7f8..40e14adfc 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design. + +### Additional Evidence (extend) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16* + +Aon data shows benefits scale dramatically with adherence: 80%+ adherent users show 9 percentage point lower cost growth (vs 6 points for all users) in diabetes and 7 points lower (vs 3 points) in weight loss. This confirms that the adherence crisis undermines the economic case, but also shows the potential value if adherence can be improved. + --- Relevant Notes: diff --git a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md index 5299ec097..e4d2739f0 100644 --- a/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md +++ b/domains/health/semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md @@ -28,6 +28,12 @@ This is the first dedicated kidney outcomes trial with a GLP-1 receptor agonist, - FDA indication expansion to T2D patients with CKD (2024) - Dialysis cost benchmark: $90K+/year per patient + +### Additional Evidence (confirm) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16* + +Aon's real-world data confirms downstream cost savings materialize after 12-18 months, with diabetes patients showing 6-9 percentage point lower medical cost growth at 30 months. This validates the kidney protection economic model—savings are real but require long-term risk-bearing to capture. + --- Relevant Notes: diff --git a/domains/health/the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md b/domains/health/the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md index 8b080952f..942c3afbc 100644 --- a/domains/health/the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md +++ b/domains/health/the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md @@ -297,6 +297,12 @@ The Commonwealth Fund's 2024 international comparison provides evidence that the C-SNP growth of 71% in one year shows MA plans are rapidly building chronic disease management infrastructure. With 21% of MA enrollment now in SNPs (up from 14% in 2020), the market is structurally shifting toward continuous care management models that align with prevention-first economics. + +### Additional Evidence (confirm) +*Source: [[2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction]] | Added: 2026-03-16* + +GLP-1 economics demonstrate the payment alignment requirement: identical drug, identical clinical outcomes, but opposite financial incentives for short-term (employer) vs long-term (MA) risk-bearers. The 12-18 month lag between costs and savings means only aligned payment structures can profit from prevention. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json b/inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json new file mode 100644 index 000000000..e90a2d958 --- /dev/null +++ b/inbox/archive/.extraction-debug/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "glp-1-receptor-agonists-reduce-female-cancer-incidence-by-14-50-percent-across-breast-and-ovarian-cancer.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:set_created:2026-03-16", + "glp-1-receptor-agonists-reduce-female-cancer-incidence-by-14-50-percent-across-breast-and-ovarian-cancer.md:set_created:2026-03-16" + ], + "rejections": [ + "glp-1-cost-effectiveness-requires-long-term-risk-bearing-because-savings-lag-drug-costs-by-12-18-months.md:missing_attribution_extractor", + "glp-1-receptor-agonists-reduce-female-cancer-incidence-by-14-50-percent-across-breast-and-ovarian-cancer.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md b/inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md index 0caf70348..fafc2bd0d 100644 --- a/inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md +++ b/inbox/archive/2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction.md @@ -7,9 +7,13 @@ date: 2026-01-13 domain: health secondary_domains: [internet-finance] format: report -status: unprocessed +status: enrichment priority: high tags: [glp-1, employer-costs, cancer-risk, cardiovascular, cost-offset, real-world-evidence] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -49,3 +53,14 @@ WHY ARCHIVED: The temporal cost dynamics (costs up Y1, down Y2+) are the most im EXTRACTION HINT: Focus on the temporal cost curve and what it implies for different payment models. The cancer finding is separately important but preliminary. flagged_for_rio: ["GLP-1 cost dynamics have direct implications for health investment thesis — long-term risk-bearers capture savings that short-term payers miss"] + + +## Key Facts +- Aon analyzed 192,000+ GLP-1 users in U.S. commercial health claims data +- First 12 months on Wegovy/Zepbound: medical costs rise 23% vs 10% for non-users +- After 12 months: medical costs grow 2% vs 6% for non-users +- Diabetes indication: 6 percentage points lower cost growth at 30 months; 9 points with 80%+ adherence +- Weight loss indication: 3 points lower cost growth at 18 months; 7 points with consistent use +- Female GLP-1 users: ~50% lower ovarian cancer incidence, 14% lower breast cancer incidence +- MACE reduction: 47% for women, 26% for men among adherent users +- Also associated with lower osteoporosis, rheumatoid arthritis, alcohol/drug abuse hospitalizations